Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
Agarwal K, Buti M, van Bömmel F, Lampertico P, Janczewska E, Bourliere M, Vanwolleghem T, Lenz O, Verbinnen T, Kakuda TN, Mayer C, Jezorwski J, Muenz D, Beumont M, Kalmeijer R, Biermer M, Lonjon-Domanec I. Agarwal K, et al. Among authors: van bommel f. J Hepatol. 2024 Apr 5:S0168-8278(24)00231-9. doi: 10.1016/j.jhep.2024.03.046. Online ahead of print. J Hepatol. 2024. PMID: 38583491 Free article.
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Sonneveld MJ, et al. Among authors: van bommel f. J Hepatol. 2022 May;76(5):1042-1050. doi: 10.1016/j.jhep.2022.01.007. Epub 2022 Jan 29. J Hepatol. 2022. PMID: 35092743 Free article.
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study.
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Sonneveld MJ, et al. Among authors: van bommel f. JHEP Rep. 2023 May 12;5(8):100790. doi: 10.1016/j.jhepr.2023.100790. eCollection 2023 Aug. JHEP Rep. 2023. PMID: 37484211 Free PMC article.
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertoletti A, Lampertico P. Loglio A, et al. Among authors: van bommel f. J Hepatol. 2019 Oct;71(4):834-839. doi: 10.1016/j.jhep.2019.07.003. Epub 2019 Jul 11. J Hepatol. 2019. PMID: 31302176
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Loglio A, et al. Among authors: van bommel f. J Hepatol. 2022 Feb;76(2):464-469. doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23. J Hepatol. 2022. PMID: 34699951
Flares during long-term entecavir therapy in chronic hepatitis B.
Chi H, Arends P, Reijnders JG, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen BE, Janssen HL; VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance). Chi H, et al. Among authors: van bommel f. J Gastroenterol Hepatol. 2016 Nov;31(11):1882-1887. doi: 10.1111/jgh.13377. J Gastroenterol Hepatol. 2016. PMID: 27008918
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE).
Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Sonneveld MJ, et al. Among authors: van bommel f. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e784-e793. doi: 10.1016/j.cgh.2020.12.005. Epub 2020 Dec 10. Clin Gastroenterol Hepatol. 2022. PMID: 33309804 Free article.
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis.
Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro-Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M. Brunetto MR, et al. Among authors: van bommel f, van der eijk a. Aliment Pharmacol Ther. 2021 Mar;53(6):733-744. doi: 10.1111/apt.16258. Epub 2021 Jan 19. Aliment Pharmacol Ther. 2021. PMID: 33465257 Free article.
HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers.
Roade L, Riveiro-Barciela M, Pfefferkorn M, Sopena S, Palom A, Bes M, Rando-Segura A, Casillas R, Tabernero D, Rodríguez-Frías F, Berg T, Esteban R, van Bömmel F, Buti M. Roade L, et al. Among authors: van bommel f. JHEP Rep. 2023 Jul 13;5(10):100842. doi: 10.1016/j.jhepr.2023.100842. eCollection 2023 Oct. JHEP Rep. 2023. PMID: 37745192 Free PMC article.
99 results